吉非替尼片辅助治疗非小细胞肺癌的临床疗效及其影响因素分析

Clinical Effects of Gefitinib Tablets in Auxiliary Treatment of Non-small Cell Lung Cancer and its Influencing Factors

目的探讨吉非替尼片辅助治疗非小细胞肺癌的临床疗效、安全性及其影响因素。方法选择我院46例既往接受化疗治疗效果不佳的非小细胞肺癌患者为研究对象,在对症支持治疗基础上加用吉非替尼片进行生物靶向治疗,治疗1个月后,观察治疗疗效及不良反应的发生情况,并分析影响疗效的因素。结果本组46例患者临床治疗显效30例(65.22%),有效16例(34.78%),未出现无效患者。共13例患者治疗过程中发生不良反应,总发生率为28.26%,其中严重不良反应4例,发生率为8.70%。因不良反应而被迫停止用药的患者仅有3例,其余患者采取相应措施后不良反应症状好转。性别、年龄、吸烟情况与WHO体力评分均与患者治疗后平均生存时间具有明显相关性,对吉非替尼治疗效果产生较大影响,吉非替尼治疗后患者临床症状得到明显改善。结论吉非替尼片辅助治疗非小细胞肺癌的临床疗效显著,但受患者年龄、性别、吸烟情况及WHO体力评分等多方面因素影响。

Objective To explore the clinical efficacy, safety and influencing factors of auxiliary treatment of non-small cell lung cancer by Gefitinib tablets. Methods Forty-six patients with NSCLC whose previous chemotherapy treatment were not optimal were selected as the objects, and all patients received biological target therapy by Gefitinib Tablets, on the basis of sup- porting treatment with retention enema. The curative effects and adverse effects were observed and the influencing factors were analyzed after one month of treatment. Results Of 46 patients, 30 cases （65.22%） had marked improvement, and 16 cases （34.78%0 had effective results, and no patient showed invalid results. A total of 13 patients had adverse reactions during the process of treatment, and the total incidence was 28.26%, including four cases with serious adverse events, with the incidence of 8.70%. Only three cases were forced to stop treatment due to adverse reactions, and the rest of the patients had symptoms of adverse reactions improved by taking corresponding measures. Gender, age, smoking status, and the WHO performance status score had obvious correlation with the patients average survival time after treatment, and had an impact on the therapeutic effects of Gefitinib Tab- lets. After treatment, patients＇ clinical symptoms significantly improved. Conclusion Gefitinib Tablets had obvious chnical curative effect in the auxiliary treatment of non-small cell lung cancer, however its curative results were affected by patients＇ age, gender, smoking status, and the WHO performance status score.